SCHEMBL4001708

SCHEMBL4001708

CN(C)c1ccc(C(=O)C(=O)Nc2ccc(S(=O)(=O)O)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.51
NPC1 O15118 4/20 0.51
RXFP1 Q9HBX9 2/20 0.49
PPARG P37231 1/20 0.49
NR2E3 Q9Y5X4 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
MAPT P10636 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
GAA P10253 1/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HSD17B10 Q99714 2/20 0.44
POLB P06746 1/20 0.44
LMNA P02545 2/20 0.44
TP53 P04637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8748004 0.85 ALDH1A1 (0.59) RAB9ARXFP1MAPTSMN1; SMN2CA1
SCHEMBL9812449 0.79 RAB9A (0.51) RAB9ANPC1RXFP1PPARGNR2E3
SCHEMBL18900607 0.78 ALDH1A1 (0.51) RAB9ANPC1RXFP1PPARGNR2E3
SCHEMBL1134428 0.78 ALDH1A1 (0.55) RAB9ANPC1MAPTSMN1; SMN2CA12
SCHEMBL27333040 0.76 ALDH1A1 (0.53) RAB9ANPC1MAPTSMN1; SMN2CA12
Hydrochloric Acid SCHEMBL28095718 0.76 ALDH1A1 (0.53) RAB9ANPC1MAPTSMN1; SMN2CA12
SCHEMBL21568088 0.76 MAPT (0.71) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL9449429 0.72 CA2 (0.77) RXFP1MAPTCA12CA1CA2
SCHEMBL28203165 0.72 ALDH1A1 (0.50) RAB9ANPC1MAPTSMN1; SMN2CA12
SCHEMBL11859460 0.71 CA1 (0.70) RAB9ANPC1MAPTCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066619-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS Arete Therapeutics, INC. (US) 2009-06-10 EP claimed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US claimed
WO-2008073623-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-06-19 WO claimed
EP-2066619-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS Arete Therapeutics, INC. (US) 2009-06-10 EP disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
WO-2008073623-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-06-19 WO disclosed
WO-2008073623-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 RAB9A 3155/4885NPC1 1983/4885RXFP1 2857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.